Radiofrequency ablation for papillary thyroid microcarcinoma close to the thyroid capsule versus far from the thyroid capsule: a retrospective study.

Jieli Luo, Tianchen Hui, Peile Jin, Yang Sun, Yajun Chen, Zimei Lin, Pintong Huang
{"title":"Radiofrequency ablation for papillary thyroid microcarcinoma close to the thyroid capsule versus far from the thyroid capsule: a retrospective study.","authors":"Jieli Luo, Tianchen Hui, Peile Jin, Yang Sun, Yajun Chen, Zimei Lin, Pintong Huang","doi":"10.5603/ep.95964","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to evaluate the safety and efficacy of ultrasound-guided radiofrequency ablation (RFA) for the management of papillary thyroid microcarcinoma (PTMC) close to the thyroid capsule.</p><p><strong>Material and methods: </strong>This was a retrospective study of 202 patients with PTMC who underwent RFA close to the thyroid capsule and 80 patients with PTMC who underwent RFA far from the thyroid capsule between June 2015 and December 2022. The follow-up time after RFA, change in size of tumour, location, thyroid function, the rates of PTMC disappearance, and complications were evaluated.</p><p><strong>Results: </strong>A total of 202 patients with PTMC close to the thyroid capsule and 80 patients with PTMC far from the thyroid capsule successfully treated with RFA were studied. The thyroid function including free triiodothyronine (fT3), free thyroxine (fT4), triiodothyronine (T3), thyroxine (T4), and thyroid-stimulating hormone (TSH) showed no changes after RFA for one months in both groups. The tumour size was increased at 1, 3, and 6 months after RFA compared with pre-operative RFA in both groups. The tumour size was decreased at 12 and 24 months after RFA compared with pre-operative RFA both in both group. Seventy-nine PTMC close to the thyroid capsule and 30 PTMC far from the thyroid capsule completely disappeared as assessed by ultrasound examination. Eighty-four PTMC patients close to the thyroid capsule and 34 PTMC patients far from the thyroid capsule had minor complications after RFA treatment. The complication rates between the 2 groups were similar.</p><p><strong>Conclusion: </strong>Ultrasound-guided RFA seems to be an effective and safe method for patients with PTMC close to the thyroid capsule.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"75 1","pages":"35-41"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endokrynologia Polska","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/ep.95964","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The aim of this study was to evaluate the safety and efficacy of ultrasound-guided radiofrequency ablation (RFA) for the management of papillary thyroid microcarcinoma (PTMC) close to the thyroid capsule.

Material and methods: This was a retrospective study of 202 patients with PTMC who underwent RFA close to the thyroid capsule and 80 patients with PTMC who underwent RFA far from the thyroid capsule between June 2015 and December 2022. The follow-up time after RFA, change in size of tumour, location, thyroid function, the rates of PTMC disappearance, and complications were evaluated.

Results: A total of 202 patients with PTMC close to the thyroid capsule and 80 patients with PTMC far from the thyroid capsule successfully treated with RFA were studied. The thyroid function including free triiodothyronine (fT3), free thyroxine (fT4), triiodothyronine (T3), thyroxine (T4), and thyroid-stimulating hormone (TSH) showed no changes after RFA for one months in both groups. The tumour size was increased at 1, 3, and 6 months after RFA compared with pre-operative RFA in both groups. The tumour size was decreased at 12 and 24 months after RFA compared with pre-operative RFA both in both group. Seventy-nine PTMC close to the thyroid capsule and 30 PTMC far from the thyroid capsule completely disappeared as assessed by ultrasound examination. Eighty-four PTMC patients close to the thyroid capsule and 34 PTMC patients far from the thyroid capsule had minor complications after RFA treatment. The complication rates between the 2 groups were similar.

Conclusion: Ultrasound-guided RFA seems to be an effective and safe method for patients with PTMC close to the thyroid capsule.

靠近甲状腺囊与远离甲状腺囊的甲状腺乳头状微癌射频消融术:一项回顾性研究。
引言本研究旨在评估超声引导下射频消融术(RFA)治疗靠近甲状腺囊的甲状腺乳头状微小癌(PTMC)的安全性和有效性:这是一项回顾性研究,研究对象为2015年6月至2022年12月期间接受RFA治疗的202例靠近甲状腺囊的PTMC患者和接受RFA治疗的80例远离甲状腺囊的PTMC患者。对RFA术后随访时间、肿瘤大小变化、位置、甲状腺功能、PTMC消失率和并发症进行了评估:共有202名靠近甲状腺囊的PTMC患者和80名远离甲状腺囊的PTMC患者成功接受了RFA治疗。两组患者的甲状腺功能(包括游离三碘甲状腺原氨酸(fT3)、游离甲状腺素(fT4)、三碘甲状腺原氨酸(T3)、甲状腺素(T4)和促甲状腺激素(TSH))在 RFA 治疗 1 个月后均无变化。与术前相比,两组患者在 RFA 术后 1、3 和 6 个月的肿瘤大小均有所增加。与术前相比,两组患者在 RFA 术后 12 个月和 24 个月的肿瘤体积均有所缩小。经超声检查评估,79 例靠近甲状腺囊的 PTMC 和 30 例远离甲状腺囊的 PTMC 完全消失。84名靠近甲状腺囊的PTMC患者和34名远离甲状腺囊的PTMC患者在RFA治疗后出现了轻微并发症。两组患者的并发症发生率相似:结论:对于甲状腺囊附近的PTMC患者来说,超声引导下的RFA似乎是一种有效而安全的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.60
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信